We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

This study has been terminated.
(Enrollment was halted prematurely due to slow accrual.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00702923
First Posted: June 20, 2008
Last Update Posted: May 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Wisconsin, Madison
  Purpose
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer. This is a dose escalation study with safety the primary endpoint. Secondary endpoints will be to determine whether prostate associated immune responses are seen, and whether treatment is associated with an increase in PSA doubling time and PSA recurrence at one year, as markers of clinical activity. Cohorts of six patients will be treated in each dose level. The investigators hypothesize that short-term androgen deprivation therapy will elicit prostate cancer-associated T-cell mediated tissue destruction that can be augmented with a monoclonal antibody blocking CTLA-4, and that this will have therapeutic benefit in patients with recurrent prostate cancer.

Condition Intervention Phase
Prostate Cancer Drug: Bicalutamide and CP-675,206 (Tremelimumab) Drug: Bicalutamide, CP-675,206 (tremelimumab) Drug: Bicalutamide, CP-675,206 (Tremelimumab) Drug: Bicalutamide, CP-675,206 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Resource links provided by NLM:


Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • The Number of Participants Who Developed Cancer Antigen-specific Immune Responses [ Time Frame: Up to 12 months after treatment with study agent ]

Secondary Outcome Measures:
  • The Number of Participants With an Increase in PSA Doubling Time [ Time Frame: Up to 18 months after last dose of study agent ]
  • Number of Participants With PSA Recurrence. [ Time Frame: one year ]
    PSA recurrence is defined as a minimum PSA value of greater or equal to 1.0ng/ml occurring within one year after the last treatment with CP-675,206, with a confirmatory PSA blood teat performed at least 2 weeks later.


Enrollment: 12
Study Start Date: July 2008
Study Completion Date: March 2013
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
Drug: Bicalutamide and CP-675,206 (Tremelimumab)

Dose level -1 :

Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Other Names:
  • Casodex
  • Tremelimumab
Drug: Bicalutamide, CP-675,206 (tremelimumab)

Dose level 1:

Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Other Names:
  • Casodex
  • Tremelimumab
Drug: Bicalutamide, CP-675,206 (Tremelimumab)

Dose level 2:

Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Other Names:
  • Casodex
  • Tremelimumab
Drug: Bicalutamide, CP-675,206 (Tremelimumab)

Dose level 3:

Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Other Names:
  • Casodex
  • Tremelimumab
Drug: Bicalutamide, CP-675,206

Final Dose Level:

Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112

At month 9, if evidence of PSA progression:

Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29

Other Names:
  • Casodex
  • Tremelimumab

Detailed Description:
This is an open label, single-center Phase I study. All subjects will receive bicalutamide 150mg orally days 1-28. Subjects will receive CP-675,206 IV over one hour on day 29. Doses will range from 6 mg/kg to 15 mg/kg. This cycle will be repeated once at month 3. Once the maximum tolerated dose has been determined, up to 6 additional subjects will be enrolled.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age & histologic diagnosis of adenocarcinoma of the prostate
  • Completed surgery or radiation at least 8 weeks prior to entry with removal of all visible disease
  • Clinical Stage D0 prostate cancer with rising PSA and PSA >2ng/ml.
  • ECOG performance of <2
  • Normal hematologic, renal and liver function

Exclusion Criteria:

  • Cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy.
  • No prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex or flutamide
  • No evidence for metastatic disease per bone scan or CT scan of the abdomen and pelvis
  • No prior treatment with anti-CTLA 4 monoclonal antibody
  • No history of known autoimmune disorder or HIV, hepatitis B or hepatitis C
  • No known brain metastases
  • No history of inflammatory bowel conditions including diverticulitis, ulcerative colitis, etc.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00702923


Locations
United States, Wisconsin
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Pfizer
Investigators
Principal Investigator: Douglas McNeel, MD, PhD University of Wisconsin, Madison
Principal Investigator: Douglas McNeel, M.D., PhD University of Wisconsin, Madison
  More Information

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00702923     History of Changes
Other Study ID Numbers: CO07808
First Submitted: June 18, 2008
First Posted: June 20, 2008
Results First Submitted: February 24, 2014
Results First Posted: May 7, 2014
Last Update Posted: May 7, 2014
Last Verified: April 2014

Keywords provided by University of Wisconsin, Madison:
Stage D0 Prostate Cancer
Rising PSA
Casodex
Tremelimumab

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Androgens
Tremelimumab
Bicalutamide
Antibodies, Monoclonal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Immunologic Factors
Androgen Antagonists
Hormone Antagonists